HIGHLIGHTS
- who: William D. Lubell from the Département have published the research work: Peptide-Based Drug Development, in the Journal: Biomedicines 2022, 10, 2037. of 16/08/2022
SUMMARY
Bolstered by a higher rate of clinical trial success than small_molecules, the ability to affect previously considered ‘undruggable' targets such as protein-protein interactions, and a lower production cost compared to biologics, peptides now command an enviable position in the drug discovery and development process due in great part to high potency, keen specificity, and low toxicity. The expansion of the field of peptide . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.